Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

医学 内科学 癌症 肺癌 黑色素瘤 不利影响 回顾性队列研究 队列 肿瘤科 泌尿生殖系统 人口 临床试验 环境卫生 癌症研究
作者
Caroline A. Nebhan,Alessio Cortellini,Weijie Ma,Teja Ganta,Haocan Song,Fei Ye,Rebecca Irlmeier,Neha Debnath,Anwaar Saeed,Maluki Radford,Asrar Alahmadi,Akiva Diamond,Christopher Hoimes,Nikhil H. Ramaiya,Carolyn J. Presley,Dwight H. Owen,Sarah Abou Alaiwi,Amin H. Nassar,Biagio Ricciuti,Giuseppe Lamberti,Melissa Bersanelli,Chiara Casartelli,Sebastiano Buti,Paolo Marchetti,Raffaele Giusti,Marco Filetti,Vito Vanella,Domenico Mallardo,Shravanti Macherla,Tamara A. Sussman,Andrea Botticelli,Domenico Galetta,Annamaria Catino,Pamela Pizzutilo,Carlo Genova,Maria Giovanna Dal Bello,Foteini Kalofonou,Ella Daniels,Paolo A. Ascierto,David J. Pinato,Toni K. Choueiri,Douglas B. Johnson,Thomas U. Marron,Yinghong Wang,Abdul Rafeh Naqash
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (12): 1856-1856 被引量:97
标识
DOI:10.1001/jamaoncol.2021.4960
摘要

Importance

Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population.

Objective

To provide insight into the clinical outcomes and safety of ICIs among geriatric patients (aged ≥80 years) with cancer.

Design, Setting, and Participants

A Multicenter, international retrospective study of 928 geriatric patients with different tumors treated with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe. Analyses were conducted from January 2021 to April 2021.

Main Outcomes and Measures

Clinical outcomes and irAE patterns in geriatric patients treated with single-agent ICIs.

Results

Median (range) age of the 928 patients at ICI initiation was 83.0 (75.8-97.0) years. Most patients (806 [86.9%]) were treated with anti–programmed cell death 1 therapy. Among the full cohort, the 3 most common tumors were non–small cell lung cancer (NSCLC, 345 [37.2%]), melanoma (329 [35.5%]), and genitourinary (GU) tumors (153 [16.5%]). Objective response rates for patients with NSCLC, melanoma, and GU tumors were 32.2%, 39.3%, and 26.2%, respectively. Median PFS and OS, respectively, were 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU). Within histologically specific subgroups (NSCLC, melanoma, and GU), clinical outcomes were similar across age subgroups (aged <85 vs ≥85 years). Among all 928 patients, 383 (41.3%) experienced ≥1 irAE(s), including 113 (12.2%) that were reported to be grade (G) 3 to 4 based on Common Terminology Criteria for Adverse Events (version 5.0). The median time to irAE onset was 9.8 weeks; 219 (57%) occurred within the first 3 months after ICI initiation. Discontinuation of treatment with ICIs owing to irAEs occurred in 137 (16.1%) patients. There was no significant difference in the rate of irAEs among patients aged younger than 85, 85 to 89, and 90 years or older. Despite the similar rate of G3 or higher irAEs, ICIs were discontinued due to irAEs more than twice as often among patients aged 90 years or older compared with patients younger than 90 years (30.9% vs 15.1%,P = .008).

Conclusions and Relevance

The findings of this international cohort study suggest that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, though ICI discontinuation owing to irAEs was more frequent with increasing age.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
龙成阳完成签到,获得积分10
1秒前
cc完成签到,获得积分10
1秒前
安陌煜发布了新的文献求助10
1秒前
2秒前
4秒前
7秒前
科研通AI2S应助ZhangXR采纳,获得10
7秒前
华仔应助tanglu采纳,获得10
8秒前
11秒前
13秒前
15秒前
BoBo完成签到 ,获得积分10
15秒前
16秒前
kiki完成签到,获得积分10
16秒前
Dada应助滕皓轩采纳,获得30
16秒前
18秒前
kiki发布了新的文献求助10
20秒前
yzWang发布了新的文献求助10
20秒前
科研通AI2S应助LY采纳,获得10
20秒前
謃河鷺起完成签到,获得积分10
20秒前
Mia发布了新的文献求助10
21秒前
小蘑菇应助兴球采纳,获得10
21秒前
勤奋的寒风完成签到,获得积分10
23秒前
24秒前
123完成签到,获得积分10
25秒前
ChenJohnny应助有道理采纳,获得50
26秒前
26秒前
27秒前
量子星尘发布了新的文献求助10
28秒前
tingalan完成签到,获得积分10
29秒前
研友_VZG7GZ应助林平之采纳,获得10
29秒前
yzWang完成签到,获得积分10
29秒前
爆米花应助科研通管家采纳,获得10
30秒前
汉堡包应助科研通管家采纳,获得80
30秒前
乐乐应助科研通管家采纳,获得10
30秒前
30秒前
chen应助科研通管家采纳,获得10
30秒前
酷波er应助科研通管家采纳,获得10
30秒前
温冰雪应助科研通管家采纳,获得30
30秒前
李健应助科研通管家采纳,获得10
30秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3958068
求助须知:如何正确求助?哪些是违规求助? 3504219
关于积分的说明 11117555
捐赠科研通 3235582
什么是DOI,文献DOI怎么找? 1788351
邀请新用户注册赠送积分活动 871204
科研通“疑难数据库(出版商)”最低求助积分说明 802511